Reading the Signals

Applying Pharma Productivity Benchmarks to Internal CI Programs

In this CI-oriented discussion, Evaluate’s competitive intelligence leaders unpack the 2026 Pipeline-to-Patient Productivity Index and show how the findings can be translated to inform indication-level competitor analyses.
Using real examples, our team will walk through how to take a macro finding, test whether it applies to your indication, and turn it into a monitoring signal to position indication-level findings against the industry benchmark.

Share:

Register today








About this webinar

Evaluate’s competitive intelligence leaders will use real examples to walk through how to move from an industry-wide benchmark to a named-competitor view, and how to turn that into a monitoring signal your CI program can act on.

The session will cover:

  • Quick takes on 2026 industry-level benchmarks and how they influence framing of competitive intelligence analyses
  • How the industry is increasingly “failing early” and what this means for interpreting your competitor’s pipelines
  • The practical value of moving from an industry-wide number down to a named-competitor view at the therapeutic area and/or indication level

Join them on October 13th for a practical session on getting more from productivity data.

Speakers

Kelly Chamberlain

Kelly Chamberlain

Partner​, Market Intelligence

Adam Schaffner

Director Consulting & Analytics

Frequently Asked Questions

The Productivity Index is an industry-level benchmarking tool that tracks how effectively the pharma industry converts pipeline assets into approved medicines. This webinar focuses on how CI teams can apply those findings to their own indication-level work.

This session is designed for competitive intelligence professionals at pharma and biotech companies who want to connect industry-level data to their day-to-day CI programs.

Practical tools for applying macro productivity benchmarks to indication-level competitor analysis, including how to identify monitoring signals and frame findings against industry norms.

Yes, the session is free to attend and materials will be available afterward.

Explore all webinars